

Please refer to Phase I studies for more clinical trial opportunities

Melanoma	
Adjuvant Therapies	
Stage 2b or 2c	Stage 2b, 2c or 3
IRB# 19679 Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study	IRB#11848 Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

CROSS-DISEASE TRIALS:

IRB# TBD EAY131 (MATCH)	IRB# TBD S1609 (DART)
--------------------------------------	---------------------------------

Melanoma			
Observational	Uveal Melanoma	Stage 3 or 4 Resectable	
IRB#17104 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study	IRB# 21536 A Phase 2 trial of AU-011 via suprachoroidal administration designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma	IRB#15661 A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma	IRB #16883 A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection Moderna A Phase II randomized study of adjuvant immunotherapy with Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma
			IRB# 21882 A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Key

- Open for Enrollment
- In Development
- Enrollment on Hold



Please refer to Phase I studies for more clinical trial opportunities

Melanoma

Stage 3 or 4, Unresectable

Mutation Specific

[IRB# 19667](#)
[A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib+ Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis](#)

Melanoma

Stage 3 or 4, Unresectable

Non-Mutation Specific

IRB 16198
 A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

[IRB# 18687](#) [A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in participants with previously untreated unresectable or metastatic melanoma.](#)

[IRB# 19207](#)
[A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab \(MK-3475\) and Lenvatinib\(E7080/MK-7902\) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma \(LEAP-003\)](#)

[IRB# 19943](#)
[A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma](#)

[IRB# 19285](#)
[A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma](#)

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

11/18/2020

Melanoma + Non-melanoma skin cancer

IRB 22389:
A Phase 1b/2
Study of
Cavrotolimod
Combined with
Pembrolizumab or
Cemiplimab in
Patients with
Advanced Solid
Tumors



11/18/2020

<http://www.ohsu.edu/research/rda/so/knight.php>

Key

-  Open for Enrollment
-  In Development
-  Enrollment on Hold